The emergence of HER2-low cancers as a distinct therapeutic category represents a watershed moment in modern oncology, fundamentally altering treatment approaches for a previously underserved patient population. This breakthrough has catalyzed the development of the HER2 Low Cancers Market, creating new possibilities for targeted therapy and precision medicine. As...